Heo Jung, Ryu Hyun Jin, Park Hyunju, Kim Tae Hyuk, Kim Sun Wook, Oh Young Lyun, Chung Jae Hoon
Division of Endocrinology and Metabolism, Department of Internal Medicine, Myongji Hospital, Hanyang University College of Medicine, 55, Hwasu-ro 14 beongil, Deokyang-gu, Goyang-si, Gyeonggi-do, Korea.
Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, Korea.
Endocrine. 2024 Mar;83(3):671-680. doi: 10.1007/s12020-023-03510-8. Epub 2023 Oct 9.
Papillary thyroid microcarcinoma (PTMC) has an excellent prognosis; however, some PTMCs exhibit poor outcomes. Cancer-specific death from PTMC has been rarely reported, so we aimed to evaluate mortality rates and causes of death in patients who died with PTMC.
We retrospectively reviewed 8969 PTMC patients treated at Samsung Medical Center from 1994 to 2017. Mortality rate and causes of death in PTMC patients were evaluated and compared with those of 7873 patients with papillary thyroid carcinoma (PTC) > 1 cm. In addition, we reviewed previous publications reporting cancer-specific deaths from PTMC.
Among the 8969 PTMC patients, 107 (1.2%) patients died. Only two (0.02%) patients have died of PTMC, which was less than the cancer-specific deaths from PTC > 1 cm (0.71%). Among the deceased PTMC patients, 63 (58.9%) died of other malignancies, three (2.8%) died of cardiovascular diseases, and five (4.7%) died of other diseases. Compared with PTC > 1 cm, cancer-specific deaths was less (1.9% vs. 15.1%, P < 0.001), and deaths from other malignancies were higher in deceased PTMC patients (58.9% vs. 30.5%, P < 0.001). According to 18 studies, PTMC-specific mortality rates ranged from 0.05% to 14.3%, and 336 cancer-specific deaths (0.43%) occurred among 78,770 PTMC patients.
The cancer-specific mortality rate of PTMC patients was extremely low (0.02%). More than half of deceased PTMC patients died of other malignancies, which was significantly more than those with PTC > 1 cm. These results support that active surveillance can be selected as a therapeutic option for PTMC.
甲状腺微小乳头状癌(PTMC)预后良好;然而,部分PTMC患者预后较差。PTMC导致的癌症特异性死亡鲜有报道,因此我们旨在评估死于PTMC患者的死亡率及死亡原因。
我们回顾性分析了1994年至2017年在三星医疗中心接受治疗的8969例PTMC患者。评估PTMC患者的死亡率及死亡原因,并与7873例甲状腺乳头状癌(PTC)直径>1 cm的患者进行比较。此外,我们查阅了先前报道PTMC癌症特异性死亡的文献。
8969例PTMC患者中,107例(1.2%)死亡。仅2例(0.02%)患者死于PTMC,低于PTC直径>1 cm患者的癌症特异性死亡率(0.71%)。在已故的PTMC患者中,63例(58.9%)死于其他恶性肿瘤,3例(2.8%)死于心血管疾病,5例(4.7%)死于其他疾病。与PTC直径>1 cm的患者相比,PTMC患者的癌症特异性死亡率更低(1.9%对15.1%,P<0.001),已故PTMC患者死于其他恶性肿瘤的比例更高(58.9%对30.5%,P<0.001)。根据18项研究,PTMC特异性死亡率在0.05%至14.3%之间,78770例PTMC患者中发生336例癌症特异性死亡(0.43%)。
PTMC患者的癌症特异性死亡率极低(0.02%)。超过半数已故PTMC患者死于其他恶性肿瘤,显著多于PTC直径>1 cm的患者。这些结果支持可将主动监测作为PTMC的一种治疗选择。